Knee osteoarthritis
Conditions
Interventions
Treatment group:Needle-knife treatment using the "tendon-regulating and bone-setting", with needle-knife treatment points selected at the anterior, lateral, posterior and medial sides of the knee join
Control group:Oral celecoxib capsules (Celebrex, Pfizer Pharmaceuticals, NDT: J20140072,200 mg), 200 mg once daily for 3 weeks.
Sponsors
The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: a. Meet the diagnostic criteria of the Chinese Osteoarthritis Diagnosis and Treatment Guidelines (2021 edition) issued by the Chinese Medical Association. b. No other systemic diseases; c. No medication or other treatment in the last 2 weeks; d. Sign the informed consent form and participate in the experiment regularly according to the requirements of the experiment.
Exclusion criteria
Exclusion criteria: a. Unable to cooperate or unsuitable for needle knife treatment; b. Allergy to sulfonamides; c. Patients with heart, liver, kidney and other primary diseases or mental diseases; d. Patients with other knee joint diseases (such as infection, tuberculosis, rheumatoid, trauma, skin disease, etc.); e. Pregnant and breast-feeding females; f. Patients with critical conditions who are difficult to independently evaluate the efficacy and safety of the treatment; g. Those who have difficulty in adhering to the established program of treatment and affecting the progress of the subject.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| T2*mapping analysis;Gait analysis;Visual Analogue Scale (VAS);Knee score (HSS); | — |
Countries
China
Contacts
Public ContactZheng Zhiweng
The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Outcome results
None listed